CRISPR Therapeutics AG
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-581.6M | $-366.3M | $-153.6M | $-650.2M | $377.7M | $-348.9M | $66.9M | $-165.0M |
| Depreciation & Amortization | $19.5M | $19.3M | $19.8M | $24.2M | $18.0M | $9.2M | $4.7M | $3.5M |
| Depreciation | $19.4M | $19.2M | $19.8M | $24.1M | $17.9M | $9.1M | $4.7M | $3.5M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $72.5M | $86.6M | $81.0M | $97.9M | $102.4M | $66.0M | $44.1M | $35.0M |
| Net Cash from Operating Activities | $-345.0M | $-142.8M | $-260.4M | $-495.7M | $539.0M | $-238.4M | $56.7M | $-96.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $914.0K | $1.9M | $9.5M | $37.2M | $81.7M | $18.4M | $6.7M | $2.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-31.8M | $-280.5M | $374.6M | $-258.7M | $-1.04B | $-541.2M | $1.3M | $-2.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | $57.0K |
| Net Cash from Financing Activities | $426.0M | $332.0M | $62.7M | $38.6M | $250.9M | $1.02B | $431.0M | $315.9M |
| Net Change in Cash | $49.3M | $-91.3M | $177.0M | $-715.9M | $-245.5M | $236.7M | $489.0M | $216.9M |
| Free Cash Flow | $-345.9M | $-144.7M | $-269.8M | $-532.9M | $457.3M | $-256.7M | $50.0M | $-99.0M |